Document is current
Any future updates will be listed below
-
Authors
Gao, Julia L. https://orcid.org/0000-0001-8420-8594
Otto, Tracey S. https://orcid.org/0000-0002-6385-0470
Porter, Martina L. https://orcid.org/0000-0002-4738-4385
Kimball, Alexa B. https://orcid.org/0000-0001-9405-0479
- License Information
-
More Information
Article History
Accepted: 8 July 2024
First Online: 26 July 2024
Declarations
:
: Not applicable.
: Dr. Alexa B. Kimball’s institution received grants from Abbvie, Admirx, Anapyts Bio, Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, Prometheus, UCB, and Sonoma Bio. Drs. Gao and Otto received fellowship funding from Janssen and Abbvie. Dr. Kimball received consulting fees from Abbvie, Alumis, Bayer, Boehringer Ingelheim, Eli Lilly, Evoimmune, Janssen, Moonlake, Novartis, Pfizer, Priovant, Sonoma Bio, Sanofi, UCB, and Target RWE; and she serves on the board of directors of Almirall. Dr. Martina Porter is a consultant and/or investigator for Abbvie, Bristol Meyers Squibb, Janssen, Eli Lilly, Moonlake, Novartis, Pfizer, SonomaBio, Trifecta Clinical (on behalf of Acelyrin), UCB, Aristea, Regeneron, Innovoderm, Bayer, Alumis, Sanofi, and Incyte.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Material preparation was performed by Julia Gao, MD. The first draft of the manuscript was written by Julia Gao, MD, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
: Exempt from review.
